Ikarian Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ikarian Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-450,000	Closed	-$3.23M	–	206
2025 Q3	$3.23M	Buy	450,000 +255,500	+131%	+$13.3M	0.33%	79
2025 Q2	$9.18M	Buy	194,500 +100,000	+106%	+$4.07M	1.76%	20
2025 Q1	$3.69M	Buy	+94,500	New	+$4.07M	0.46%	47
2024 Q2	–	Sell	-158,000	Closed	-$7.94M	–	146
2024 Q1	$7.94M	Sell	158,000 -42,600	-21%	-$2.31M	0.87%	38
2023 Q4	$12.1M	Buy	+200,600	New	+$10.3M	1.13%	29

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Ikarian Capital's MLTX Position: Q4 2025 in Review

Ikarian Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 435,839 shares — an estimated $3.12M sold.

Ikarian Capital first reported a position in MLTX in Q3 2025 and held it in 1 quarter. The position peaked at $3.12M in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

Ikarian Capital reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 435,839 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $3.12M.
Ikarian Capital first reported a position in MoonLake Immunotherapeutics in Q3 2025 and held it in 1 quarter.
Ikarian Capital's MoonLake Immunotherapeutics position peaked at $3.12M in Q3 2025.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.